$14.75
-0.20 (-1.34%)
CPRI News6 articles
Xcel Brands Surges on Coco Rocha-Baggallini Deal; Thin Float Fuels Volatility
Xcel Brands shares surged 10.5% to $2.10 on record volume after announcing an exclusive Baggallini-Coco Rocha handbag deal. The stock's tiny float of under 4 million shares amplified the move, despite ongoing financial challenges.
Capricor's FDA Delay Trims Stock to Cash-Adjusted Bet
Capricor shares dropped 8% after the FDA postponed its decision on deramiocel, leaving a slim premium above cash. Analyst targets remain sharply divided.
Capricor Shares Jump as FDA Reviews New Duchenne Data; PDUFA Date Looms
Capricor shares rose 51.7% after the FDA agreed to review new 24-month data for deramiocel, but the stock remains far below its July peak as the Aug. 22 decision date approaches.
Capricor Therapeutics Plunges 67% on FDA Concerns Over Deramiocel Efficacy
Capricor Therapeutics shares plummeted 67% after FDA staff flagged concerns about deramiocel's efficacy data, wiping out $766 million in market value ahead of a key advisory committee vote.
Market Movers: RELX, Capricor, and Global Tensions Shape Trading
RELX drops 8.8% in a week, Capricor soars 387% annually, US-Iran tensions drive crude oil volatility, and other key market movers on May 10, 2026.
Capricor Shares Gain Ahead of Key Duchenne Data and Financial Update
Capricor Therapeutics shares advanced 7.6% as the company prepares to release quarterly results and full Phase 3 data for its Duchenne muscular dystrophy drug deramiocel on March 12.